(Reuters) - The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on ...

Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock has ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its embattled chief executive face a long war against an activist that hates to ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have gained 3% on a YTD basis, significantly underperforming both the S&P 500 Index's ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Find out more about JAK inhibitors and whether they are a good option for treating inflammatory diseases and cancer.

The new COVID vaccine is here, but does it bring any new side effects or reactions? Here's what the COVID booster 2024 side ...